Scarica l'app Stockscreener
2.29
0.71%
-0.0164
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IBRX Giù?
Forum
Previsione
Immunitybio Inc Borsa (IBRX) Ultime notizie
ImmunityBio, Inc. (IBRX): A Bull Case Theory - Insider Monkey
Is ImmunityBio Inc. stock a smart buy before Fed meeting2025 Price Targets & Safe Entry Zone Tips - Newser
Will ImmunityBio Inc. (26CA) stock benefit from mergersJuly 2025 Price Swings & Breakout Confirmation Alerts - Newser
How ImmunityBio Inc. (26CA) stock responds to bond marketJuly 2025 Drop Watch & Intraday High Probability Alerts - Newser
Piper Sandler Remains a Buy on ImmunityBio (IBRX) - The Globe and Mail
Is ImmunityBio Inc. (26CA) stock undervalued at current priceWeekly Profit Recap & Reliable Volume Spike Trade Alerts - Newser
ImmunityBio (NASDAQ:IBRX) Trading Down 5.4%Should You Sell? - MarketBeat
Lawmakers Invited to FDA Meeting for Patrick Soon-Shiong’s Drug - Bloomberg.com
ImmunityBio (IBRX) Slashes 9% on Lack of Leads - Finviz
A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs (NASDAQ:IBRX) - Seeking Alpha
ImmunityBio (NASDAQ:IBRX) Sees Large Volume IncreaseStill a Buy? - MarketBeat
ImmunityBio Stock Rises Despite Financial Challenges - timothysykes.com
Can ImmunityBio Inc. (26CA) stock sustain free cash flowRisk Management & Reliable Volume Spike Trade Alerts - Newser
Geode Capital Management LLC Acquires 1,487,849 Shares of ImmunityBio, Inc. $IBRX - MarketBeat
Assessing ImmunityBio After Recent Cancer Immunotherapy Headlines and Ongoing Stock Volatility - Yahoo Finance
A Fresh Look at ImmunityBio (IBRX) Valuation After Recent Share Rally - Yahoo Finance
ImmunityBio (IBRX) Soars 10.8% Ahead of Health Conferences - Insider Monkey
ImmunityBio Skyrockets on Positive Trial Results and Sales Growth - StocksToTrade
ImmunityBio Boosts Outlook with Strong Revenue Growth and Clinical Advances - timothysykes.com
ImmunityBio’s Immunotherapy Focus Boosts Market Expectations - StocksToTrade
ImmunityBio Gains Momentum with Strong ANKTIVA Sales and Clinical Advances - timothysykes.com
Is ImmunityBio Inc. (IBRX) The Best US Stock To Buy Under $20? - Insider Monkey
10 Stocks Racking Up Big Gains - Insider Monkey
ImmunityBio Stock Boosted by Rising Demand for ANKTIVA and Positive Clinical Trials - StocksToTrade
ImmunityBio’s Strong Market Position Boosted by Recent Innovations - timothysykes.com
HEIGHTS CAPITAL MANAGEMENT, INC's ImmunityBio Inc(IBRX) Holding History - GuruFocus
ImmunityBio’s Clinical Advances and Sales Boost Highlight Market Optimism - StocksToTrade
ImmunityBio Stock (IBRX) Opinions on Q3 Revenue Growth - Quiver Quantitative
ImmunityBio (NASDAQ:IBRX) Shares Gap UpHere's Why - MarketBeat
Some Confidence Is Lacking In ImmunityBio, Inc.'s (NASDAQ:IBRX) P/S - 富途牛牛
ImmunityBio’s Strategic Developments and Financial Growth Fuel Optimism - timothysykes.com
ImmunityBio (IBRX) Stock Soars After Q3 Revenue Explosion – Can the Rally Survive a Going‑Concern Warning? - ts2.tech
Why ImmunityBio (IBRX) Is Up 13.5% After Strong Q3 Anktiva Revenue Surge Announced at Jefferies London - simplywall.st
ImmunityBio Stock Surges Amid Growing Demand and Clinical Success - StocksToTrade
ImmunityBio’s Remarkable Growth: Unpacking the Surge - StocksToTrade
ImmunityBio Explores Innovations in Cancer Treatment - timothysykes.com
ImmunityBio (IBRX) Stock Forecast and Price Target 2025 - MarketBeat
ImmunityBio (IBRX): Evaluating Valuation After Q3 Revenue Growth and Operational Improvements - simplywall.st
A Fresh $16 Million Bet on ImmunityBio: What Investors Should Know - AOL.com
What to know about Anktiva, the cancer drug that doesn’t use chemotherapy - NewsNation
How does nonchemotherapy cancer treatment Anktiva work? - NewsNation
Q3 2025 Contract Research Organization (CRO) Activity and Intel Report Featuring ICON, Astrazeneca, Akesobio, CSPPC Pharmaceutical, ImmunityBio, and Boryung - Yahoo Finance
H.C. Wainwright Asserts Buy Rating on Immunitybio Inc. (IBRX) as Net Loss Narrows on Robust Product Revenue - MSN
1.44%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):